ArticleScientific reports2017
A 'Disease Severity Index' to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis.Alzheimer's research & therapy · 2019Pooled it
- Loneliness and biomarkers of brain pathology in people with subjective cognitive decline.Scientific reports · 2025Article
- Advances in the use of structural and diffusion magnetic resonance imaging for characterizing SCD and MCI due to Alzheimer's disease.Frontiers in neuroscience · 2025Review
- Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns.Alzheimer's research & therapy · 2024Article
- Brain health registry updates: An online longitudinal neuroscience platform.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Cholinergic white matter pathways along the Alzheimer's disease continuum.Brain : a journal of neurology · 2023Article
- Promoting Advance Care Planning for Persons with Dementia: Study Protocol for the LEAD (Life-Planning in Early Alzheimer's and Other Dementias) Clinical Trial.OBM integrative and complimentary medicine · 2023Article
- The role of disability and depressive symptoms in the relation between objective cognitive performance and subjective cognitive decline.Frontiers in psychiatry · 2022Article
- The interplay between gray matter and white matter neurodegeneration in subjective cognitive decline.Aging · 2021Article
- Identification of Salicylic Acid Mechanism against Leaf Blight Disease inPathogens (Basel, Switzerland) · 2021Article
- Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease.Molecular neurodegeneration · 2020Review
- Biomarker-Based Signature of Alzheimer's Disease in Pre-MCI Individuals.Brain sciences · 2019Review
- Electrophysiological brain signatures for the classification of subjective cognitive decline: towards an individual detection in the preclinical stages of dementia.Alzheimer's research & therapy · 2019Article
- Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid.NeuroImage. Clinical · 2017Article
- Cognitive Variability during Middle-Age: Possible Association with Neurodegeneration and Cognitive Reserve.Frontiers in aging neuroscience · 2017Article
- Subjective cognitive decline as a predictor of future cognitive decline: a systematic review.Dementia & neuropsychologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subjective memory decline (SMD) is a heterogeneous condition. While SMD might be the earliest sign of Alzheimer's disease (AD), it also occurs in aging and various neurological, medical, and psychiatric conditions. Identifying those with higher risk to develop dementia is thus a major challenge. We tested a novel disease severity index generated by multivariate data analysis with numerous structural MRI measures as input. The index was used to identify SMD individuals with high risk of progression to mild cognitive impairment (MCI) or AD. A total of 69 healthy controls, 86 SMD, 45 MCI, and 38 AD patients were included. Subjects were followed up for 7.5 years. Clinical, cognitive, PET amyloid imaging and APOE ε4 data were used as outcome variables. The results showed that SMD evidenced cognitive performance intermediate between healthy controls and MCI. The disease severity index identified eleven (13%) SMD individuals with an AD-like pattern of brain atrophy. These individuals showed lower cognitive performance, increased CDR-SOB, higher amyloid burden and worse clinical progression (6.2 times higher likelihood to develop MCI, dementia or die than healthy controls). The current disease severity index may have relevance for clinical practice, as well as for selecting appropriate individuals for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.